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Summary Attention has recently focused on the possible teratogenic effects of the combination antiemetic
doxylamine succinate, dicyclomine hydrochloride and pyridoxine hydrochloride (Debendox/Bendectin)
prescribed to pregnant women. The Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC), a
case-control investigation has analysed data derived from interview reports and medical records of 555
mothers of children (under 15 years) with cancer and 1110 mothers of matched control children. Separate
analyses of interview reports and medical records both suggested that antiemetic ingestion during the index
pregnancy does not increase the risk of developing childhood malignant disease in the exposed foetus. No
dose-response relationship was evident. The lack of any significant relative risks held good for diagnostic sub-
groups and when the trimester of ingestion was considered. Our results suggest that antimetics of this type are
unlikely to be transplacental carcinogens.
In utero the developing foetus presents a sensitive
target to transplacental teratogens and carcinogens
which may be present in the maternal circulation
(Salonen, 1976), although innocuous to the mother
(Cordero & Oakley, 1983). Evidence for
transplacental teratogenesis has been documented
for both animals and humans (Tomatis & Mohr,
1973). Teratogenesis and carcinogenesis are possibly
allied processes depending on the agent and its
mode and time of action (Sullivan, 1973) with
either cancer or congenital malformations resulting
from a transplacental exposure. A major deter-
minant of the outcome will be the susceptibility
of the foetus at varying stages of development
(DiPaulo & Kotin, 1966).
Apart from iron and vitamins, antiemetics are
among the commonest groups of drugs prescribed
to pregnant women, particularly in the first
trimester, the period of most rapid foetal growth.
The present paper evaluates possible carcinogenic
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effects on the foetus of mothers taking certain
antiemetics, particularly Debendox.
The Inter-Regional Epidemiological Study of
Childhood Cancer (IRESCC) collected information
on the drug ingestion during pregnancy of mothers
whose children (under 15 years) have cancer of any
type, together with equivalent information from
mothers of matched control children. An important
aspect of the study is the availability for analysis of
data both reported at interview and abstracted
from medical records.
Materials and methods
Incident cases of childhood cancer were ascertained
from regional paediatric oncology clinics and
cancer registries in 3 geographically defined Health
Service regions of England - the West Midlands,
North West and Yorkshire. From 1980-83
interviews were completed with the parents of 555
children who were diagnosed with malignant
disease under 15 years of age, and the parents of
1110 control children. Two control children
matched for age and sex with the case child were
selected, one each from the general practioner lists
of the case child (GP control) and from paediatric
hospital admissions (H control). The detailed
C) The Macmillan Press Ltd., 1985924 P.A. McKINNEY et al.
methodology is described elsewhere (Birch et al.,
1985).
The interview covered a wide range of topics but
particular detail was acquired relating to antenatal
drug ingestion. For each individual drug the time in
pregnancy and length of course were itemised
according to the detail recalled by the interviewee.
Checklists of drug groups were used as memory
prompts. Whenever possible, every mother's
obstetric record and general practioner (GP) notes
dealing with the appropriate pregnancy were
searched for drug prescriptions. The proportions of
mothers obstetric and GP notes made available to
the study were in excess of 88% and 91%
respectively, for all cases and controls. For a few of
the 1665 mothers included in the study neither
hospital or GP notes were available for perusal.
They amounted to 4, 1, and 3 instances for case,
GP and H control mothers respectively. As the
number of unavailable notes was very low, when
comparisons between record confirmed information
were made, instances where records were
unavailable were added to the unexposed group.
The computerised record is designed to accom-
modate the coding of up to 6 antenatal drugs each
with dates of ingestion and dosage. For each drug
the source of information was coded so that data
derived from interview reports and from medical
notes could be identified for analysis. An investiga-
tion of the problems surrounding the 'agreement'
of interview reports and medical records is to
be reported elsewhere (McKinney et al., in prepara-
tion), this study suggests that data from different
sources should be analysed separately.
The coding of pregnancy drugs allowed for the
differing degrees of detail available within the
interview reports and medical notes: if drug names
were not available then broad groupings such as
'sickness tablets' were used. Our analysis includes
drugs prescribed for nausea and vomiting of
pregnancy. These are primarily antihistamine
mixtures, excluding 'white medicines' and other
antacids. A few prescriptions of antihistamines were
found associated with episodes of infectious
vomiting, travel sickness and migraine. These were
not included as a more comprehensive analysis of
the antihistamine group is planned.
Precise data were generally obtained from
hospital records and GP notes: when a drug was
prescribed the date was usually recorded although
the dose was less frequently found. If sequential
prescription dates with doses were defined the
length of a course of treatment could be estimated.
Because of the varying agreement between data
sources both the information reported at interview
and that derived from medical records was used for
the present analysis.
Case-control comparisons were carried out using
the Statistical Package for the Social Sciences
version X (SPSS, 1983). The statistical tests for the
maximum likelihood estimate of the relative risk,
showing 95% confidence intervals, were performed
on a Hewlett Packard 41CV programmable
calculator (Rothman & Boice, 1982).
Results
The numbers of case and control mothers ingesting
antenatal antiemetics is shown for diagnostic
groups in Table I. Mothers who reported or were
prescribed metoclopramide hydrochloride (Maxolon)
and prochlorperazine maleate (Stemetil) were
omitted from this and subsequent tables because
of small numbers and because these two anti-
nauseants act uniquely within this pharmaco-
logical group as dopamine antagonists by hastening
gastric emptying.
'Other antiemetics' comprising meclozine hydro-
chloride and pyridoxine hydrochloride (Ancoloxin),
promethazine theoclate (Avomine), dimenhydrate
(Dramamine, Gravol), buclizine hydrochloride and
nicotinic acid (Equivert) and cyclizine hydro-
chloride (Valoid) are combined for the analysis
to accommodate the small numbers reported or
verified. They all act solely as antihistamines
except Ancoloxin which has additional anti-
cholinergic action. There was no case control
difference in the distribution of 'other antiemetics'.
All the tables in this paper count each mother as
ingesting only one antiemetic. Doxylamine suc-
cinate, dicyclomine hydrochloride and pyridoxine
hydrochloride (Debendox, Bendectin) (DB) was
recorded preferentially. At interview 5 mothers
(IC, 2GP, 3HC) reported taking 2 antiemetics,
whereas medical notes recorded 16 such mothers
(4C, 8GP,4HC). No mothers reported or were
prescribed 3 or more different antiemetics. -
The proportion of mothers reporting or
prescribed antiemetics was similar for cases and
controls, although medical sources revealed a
slightly higher percentage of mothers taking DB
than was reported at interview.
Table II shows that at the 5% level of
probability neither DB, 'other' antiemetics or
unspecified antiemetics were associated with any
significantly increased risk for the leukaemias/
lymphomas, 'other' diagnoses or all diagnoses
combined. However, there was a significantly
decreased risk for reported DB ingestion in the
'other' diagnoses which was not supported by
medically recorded data. Within this category no
diagnostic subgroup had a significantly raised risk.
Table III indicates that the occurrence of reportedCHILDHOOD CANCER AND ANTENATAL ANTIEMETICS 925
- ay W.
UN O 00
o -
-0
-I
N 0
-I
-0l
o -0 KO
o U) m a,o o £ U o
't C C en --
- N N O en 0
N e r-O dC 0 00
I' 'IN N e n
en N N en en _
e)N1Ch en --
,t "o tn--
t e en I
- --I -
- - -
I
I
-e
_ en en -
Col-I
- - I"- -4 -
--
I" ~ I
W)
00
N
0 00
00
0
ON
'IC
Cl
Cl
-10
ON
00NC N ID-- N
- C
So S N - 'l a) '-
00 WI en WI a)14
- N,
-C
,: E0
Cl
*
0
"Z
Ml
Q)
u
t4z
M..
:z
CL4
Q)
u
:3.
0.4
Q)
u
"Z
Q-4
u
ce
4.A
S:
%
CE
a~)
*.A
x
a4)
-Z
CA)
a)..)
a)
0
a)
a).)
a)
0
a)
0
a)
0
a)
0
a)
0
a)
a)a)
-0 .
0
0
.
a)
0
0
a) '0
C)
a)
a) '0 bo-
0
a)
a)
5-
en
.2
10
-o
la.
o
0
0u
a)
a) 0
'0
0
a)
0
a)
4-
C00
0
a)
z
u)
:
0
0
u:
0
0
U
11
u)
0
0
CO
CO
*a)
a)
0
0l
CO
U
U
CO) 0
b0 .§926 P.A. McKINNEY et al.
Table II Estimated relative risks of antiemetic ingestion during pregnancy.
Debendox Other antiemetics Unspecified antiemetics
Medically Medically Medically
Reported recorded Reported recorded Reported recorded
Leukaemias/lymphomas 1.03 1.03 1.33 1.37 0.87 a
'Other' diagnoses (0.47)b 0.95 1.34 0.91 0.90 a
All diagnoses combined 0.69 0.99 1.35 1.11 0.89 a
Brackets indicate significance at 5% level. aInsufficient numbers for calculation; b95% confidence interval 0.23, 0.94.
Table III Mothers antiemetic ingestion by trimester of pregnancy for all diagnoses.
Time ofpregnancy
Ist trimester 2nd trimester 3rd trimester Time not known
Antiemetic C GP H C GP H C GP H C GP H
Debendox R 18 27 25 7 6 15 4 5 12 - 4
MR 29 30 20 7 6 11 4 4 4 4 12 6
Other antiemetic R 5 3 6 3 2 1 2 - - 2 2 -
MR 16 17 14 7 1 6 2 - 2 1 4 3
Unspecified antiemetic R 31 39 45 11 11 15 7 3 9 8 7 3
MR 1 1 3 - - - - - - - - 1
C GP H
Mother's reporting 'no antiemetics' 470 459 458
'No antiemetics' medically recorded 480 479 485
(Including few 'no records'- see text)
R =Reported at interview; MR=Medically Recorded; C=Case; HC=Hospital control; GP=General
Practitioner control.
or prescribed antiemetic ingestion was mainly in
the first trimester; case control differences were
lacking when the 3 trimesters were examined
separately. The totals in Table III do not corres-
pond to the numbers of mothers because those
cases of controls found to have taken antiemetics
in more than one trimester were accordingly
counted two or three times. No significantly
increased relative risks associating the trimester of
ingestion with childhood malignancy were found
for any diagnostic subgroup. However, in the
lymphoma group the medical records of the case
mothers recorded more instances of DB (5C,
3GP,2HC) and 'other' antiemetics (SC, 3GP, 1HC)
than controls. This difference was not statistically
significant (P=0.10) and the effect was distributed
between cases with Hodgkin's disease and non-
Hodgkin's lymphoma.
The effect of drug dosage was investigated by
looking at the length of the reported or prescribed
course of antiemetics. Table IV shows the
distribution of cases and controls in the different
categories. There are no obvious case control
differences apart from medically recorded DB
ingestion for 1-2 months. Table V shows that this
group has the only significantly increased relative
risk for any dosage or antiemetic. Mothers reported
taking DB for longer periods of time than was
evident in medical notes. There was no apparent
'dose-response' relationship between antiemetic
ingestion and the duration of a reported or
prescribed course.
Discussion
The first report of any specific drug having a
transplacental carcinogenic effect was in 1971 when
Herbst et al. documented the cases of 7 young
women exposed to diethylstilboestrol (DES) during
early gestation and who subsequently developed
clear cell adenocarcinoma of the vagina. DES is a
teratogen causing genital anomalies in exposed
children of both sexes (Bibbo et al., 1975; Gill etCHILDHOOD CANCER AND ANTENATAL ANTIEMETICS 927
Table IV Mother's antenatal antiemetic ingestion by 'dose' for all diagnoses.
Length ofcourse
1 course: Course of
more than Course of Course of 6 months Duration
Single doses 5 days 1-2 months 2-6 months or longer not known
Drug C GP H C GP H C GP H C GP H C GP H C GP H
Debendox R 3 5 4 1 4 4 2 5 4 8 9 7 4 8 10 6 4 4
MR 1 2 1 5 5 3 5 1 - 3 1 7 1 2 2 27 38 24
'Other' R 1 1 1 2 2 1 2 - - - 2 2 2 - - 2 2 2
antiemetics MR 1 1 - 4 2 3 1 - 3 - 3 1 - - - 20 16 18
Unspecified R 9 9 8 12 14 7 3 8 7 4 10 9 5 - 8 17 13 17
antiemetics MR - - - - - - - - - - - - - - - 1 1 4
Mothers taking Maxolon and Stemetil are excluded. 'No antiemetic' reported and medically recorded see Table III.
R=reported at interview; MR=prescription medically recorded.
Table V Estimated relative risks for the 'dose' of antenatal antiemetics.
Length ofcourse
I course: Course 6
Single longer than Course of Course of months or
Antiemetic doses 5 days 1-2 months 2-6 months Longer
Debendox R 0.65 0.24 0.43 0.98 0.43
MR 0.50 1.26 10.04a 0.75 0.50
Other R 0.98 1.30 b b b
antiemetics MR 2.01 1.61 0.67 b b
Unspecified R 1.0 1.11 0.39 0.41 1.22
antiemetics MR b b b b b
Results were non-significant at the 5% level apart from a. (95% confidence limits, 1.76, 57.37);
bInsufficient numbers.
al., 1977). As yet it is the only drug reported to
induce cancer and malformations at the same
anatomic sites (Miller, 1977). The extreme latency
associated with modification of embryological
development is also unique (Janerisch et al., 1979).
The search for other possible transplacental
carcinogens continues but to date both case reports
and other investigations present inconclusive
evidence, although phenytoin (Ehrenbad &
Chaganti, 1981) and alcohol (Kinney et al., 1980)
both teratogens, have been weakly associated with
childhood cancers. With the knowledge that the
same agent may vary in its transplacental action, it
seems appropriate to examine possible deleterious
effects of antiemetics and DB. The present case
control analysis shows that antiemetic ingestion in
pregnancy does not significantly increase the risk of
childhood cancer developing in the exposed foetus.
These observations are relevant because by June
1983 DB was the main antiemetic prescribed to
pregnant women, prescriptions per 100 births in the
United Kingdom increasing from 11.4 in 1966 to
60.2 in 1978 (Harron et al., 1980). In the United
States DB was marketed until 1978 when the
dicyclomine was removed from the preparation.
Congenital malformations of various types have
been associated with DB ingestion in early
pregnancy (Donnai & Harris, 1978; Rothman et al.,
1979) but the results of large prospective cohort
studies have failed to produce any evidence that DB
is teratogenic in humans (Correy & Newman, 1971;
Milkovich & van den Berg, 1976; Shapiro et al.,
1977; Smithells & Sheppard, 1978; Harron et al.,
1980; Gibson et al., 1981; Jick et al., 1981). Case
control studies have supported these findings
(Winship et al., 1984). A literature review by928 P.A. McKINNEY et al.
MacMahon (MacMahon, 1981) suggests that
although a causal association of DB and
malformations can never be absolutely denied,
evidence indicates that any teratogenic potential is
only rarely expressed. DB appears, on balance, to
lack potent teratogenic properties but this does not
exclude the possibility that it is a carcinogen.
The first trimester of pregnancy is the period of
foetal growth during which transplacental
teratogens and carcinogens may have maximum
effect. It has been suggested that DB is a low grade
teratogen when taken prior to the eighth week of
pregnancy (Hall, 1981) and studies including later
weeks of pregnancy will have little chance of
detecting the consequences of early foetal exposure.
The present study did not reveal any significant risk
to the foetus associated with ingestion during any
trimester. One result shows a negative association,
but this is unconfirmed whilst mothers of children
with 'lymphomas' had medical records which
revealed more antiemetic prescriptions in the first
trimester of pregnancy than in the matched control
mothers. This uneven distribution remains
unaffected by combining for analysis the 2
antiemetics with anticholinergic action, DB and
Ancoloxin. A more comprehensive investigation is
needed to establish any possible risk of lymphoma
following in-utero exposure to antiemetics. A case
control study of adult lymphomas has shown no
relationship between 'antihistamines' and 'anti-
nausea' drugs used for long periods (Bernard &
Cartwright, unpublished data).
Justification for preferentially counting mothers
who ingested DB and another antiemetic as DB
users, lies in the lack of case control differences in
these combination ingestions indicating that their
inclusion would not bias any case control analysis.
DB comprises 3 separate agents - dicyclomine
hydrochloride (anticholinergic), doxylamine succinate
(antihistamine) and pyridoxine hydrochloride
(vitamin B6). 'Other' antiemetics act mainly as
antihistamines and it is unlikely that they would
modify the effects of DB.
Difficulties inherent in estimating drug dosage
have prevented any investigation demonstrating
dose-response relationships for antiemetics and
congenital malformations. Our study has shown no
such relationships with regard to childhood
malignancy. The isolated statistically significant
finding of an increased risk for a 1-2 month course
of DB, is considered likely to have occurred by
chance because of the absence of any other
significant estimates within the 20 comparisons
made, the lack of a linear trend, and the wide
confidence intervals. This result becomes non-
significant if DB and Ancoloxin are combined for
analysis.
Any carcinogenic or teratogenic potential of
antiemetics needs to be considered bearing in mind
that these drugs are ingested to counteract nausea
and vomiting. It is possible that nausea and
vomiting themselves reflect an underlying metabolic
disturbance which may have an independent causal
effect. Interactive effects with antiemetics have not
been considered in this paper because, apart from
hyperemesis, nausea and vomiting were not
separately recorded from antinausea drug ingestion.
The possibility of a synergistic relationship between
tobacco and DB taken in early pregnancy has been
suggested by one study in association with
congenital anomalies particularly of the genital
tract (Gibson et al., 1981). Preliminary analyses of
our data have shown no synergistic oncogenic effect
of antiemetics with maternal smoking. A detailed
analysis of all antihistamine compounds ingested in
pregnancy is planned. Future analyses from
IRESCC will be examining the relationships
between maternal smoking, alcohol consumption
and pharmacological groups of antenatal drugs.
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